Can anyone eloborate on what did happen with this collaboration?
IntelliCell BioSciences inks research agreement with Rutgers’ N.J. Center for Biomaterials
Wednesday, November 28, 2012 11:16 AM
IntelliCell BioSciences, a regenerative medicine company developing novel technologies that address the regenerative, curative and preventative conditions of disease states with high unmet clinical needs, has entered a sponsored research agreement with the New Jersey Center for Biomaterials at Rutgers, the state university of New Jersey.
The New Jersey Center for Biomaterials will be conducting a series of research projects that will further define the unique characteristics and properties of IntelliCell's proprietary cellular population. The work will be conducted on behalf of IntelliCell under the direction of professor Joachim Kohn, a researcher and director of the New Jersey Center for Biomaterials.
Initial research will focus on documenting any differences between IntelliCell's proprietary cellular population and similar cell populations isolated from human adipose tissue using conventional methods of cell isolation. After successful completion of the initial phases of the clinical research, the company hopes to engage the New Jersey Center for Biomaterials in development projects that may lead to bioengineered products containing the proprietary IntelliCell cellular population and products under development at the New Jersey Center for Biomaterials.
"This is a truly exciting opportunity for us. We have a number of highly advanced scaffolds for regenerative therapies (e.g. re-growing bone, nerve and skin), and we expect that IntelliCell's cell populations will significantly enhance the effectiveness of our biomaterials-based scaffolds,” said Kohn. “In this collaborative research project, we are combining the outstanding cell biology expertise of IntelliCell with the expertise of our chemists and materials scientists. We believe that through this collaboration, we will be able to demonstrate the merits of interdisciplinary research efforts between industry and academia.”
Kohn added, “In addition, emerging companies like IntelliCell are the main driving force for health care innovation, and we are delighted to assist such companies with technologies under development."
Anyways if the outcome was pos/neg I believe now things have all been worked out.
Happy Investor
SVFC
AI
